NovoCure (NVCR) Net Cash Flow Growth (5y) (2019 - 2026)
NovoCure (NVCR) Net Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.14 Bn | 173.84 Bn | 6.27 Bn |
| 2 | Stryker | 128.35 Bn | 125.47 Bn | 3.81 Bn |
| 3 | Medtronic | 107.95 Bn | 98.73 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.16 Bn | 66.71 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.67 Bn | 44.00 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.83 Bn | 26.25 Bn | - |
| 9 | Koninklijke Philips | 25.36 Bn | 22.23 Bn | 2.07 Bn |
| 10 | NovoCure | 2.08 Bn | 1.63 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.87% |
| Mar 31, 2026 | -15.71% |
| Dec 31, 2025 | -89.67% |
| Sep 30, 2025 | 38.56% |
| Jun 30, 2025 | 8.72% |
| Mar 31, 2025 | -67.08% |
| Dec 31, 2024 | 5.94% |
| Sep 30, 2024 | -6.03% |
| Jun 30, 2024 | -65.26% |
| Mar 31, 2024 | 79.08% |
| Dec 31, 2023 | 37.31% |
| Sep 30, 2023 | -16.04% |
| Jun 30, 2023 | -64.95% |
| Mar 31, 2023 | 16.46% |
| Dec 31, 2022 | -105.35% |
| Sep 30, 2022 | -119.79% |
| Jun 30, 2022 | 111.28% |
| Mar 31, 2022 | -5.20% |
| Dec 31, 2021 | -98.00% |
| Sep 30, 2021 | 56.70% |